Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
colleagues\(^2\) would have made it possible to classify subjects by severity more finely, thus identifying subgroups more likely to benefit from treatment. Indeed, the presence of other organ failure in patients was not detailed except for mechanical ventilation, suggesting low-grade CRS.

Second, two findings highlighted by the authors are the decrease in C-reactive protein (CRP) and the disappearance of fever, features also reported in another study of tocilizumab in COVID-19 by Hermine and colleagues.\(^3\) Tocilizumab use is associated with an expected decrease in CRP because of its pharmacological effect. Hence the biological results suggest only tocilizumab usage, and considering the decrease of CRP as efficiency in COVID-19 treatment could be an overstatement.

Third, supplementary material shows that the standard-of-care consisted of atazanavir and hydroxychloroquine, two off-label treatments for COVID-19, further reducing the external validity of the study. In addition, up to 38% of patients in the severe group received corticosteroids, a treatment now recommended by the World Health Organization for severe COVID-19.\(^4\) Overall, isolating the individual effect of tocilizumab among these therapies is difficult, particularly in an observational study, because we do not have the results of the control group.

These limitations call into question the authors’ conclusion that tocilizumab may reduce mortality in COVID-19, especially since the publication of randomized clinical trials with negative results on mortality (Hermine and colleagues\(^3\) and Stone and colleagues\(^5\)). Further prospective studies are mandatory to define tocilizumab’s place in the therapeutic arsenal for COVID-19.

Martin Mombrun, MD  
Xavier Valette, MD  
Caen, France

**AFFILIATIONS:** From the Department of Medical Intensive Care, CHU de Caen Normandie.

**FINANCIAL/NONFINANCIAL DISCLOSURES:** None declared.

**CORRESPONDENCE TO:** Martin Mombrun, MD; e-mail: mombrun-m@chu-caen.fr

Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

**DOI:** https://doi.org/10.1016/j.chest.2020.11.069

**References**

1. Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes. *Chest*. 2020;158(4):1397-1408.

2. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. 2014;124(2):188-195.

3. Hermine O, Mariette X, Tharaux P-L, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. *JAMA Intern Med*. 2021;181(1):32-40.

4. Lamontagne F, Agoritsas T, Macdonald H, et al. A living WHO guideline on drugs for covid-19. *BMJ*. 2020;370:m3379.

5. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. *N Engl J Med*. 2020;383(24):2333-2344.

**Response**

**To the Editor:**

We reported our real-world experience with the coronavirus disease 2019 (COVID-19) during the beginning of the global pandemic as it affected the Northeastern part of the United States when there were no Food and Drug Administration-approved medications to treat COVID-19.\(^1\) Our study reflected clinical practice based on available data during that time period. In the absence of proven therapies, tocilizumab was considered a good candidate for immunomodulatory therapy, based on experience with treatment of the cytokine-release syndrome in other disease conditions. To deploy the medication to those who would likely derive the greatest benefit, we selected patients with an oxygenation requirement and an elevated C reactive protein level. Though using a standard definition of cytokine-release syndrome may have been useful, our study definitions reflected real-world clinical decision-making rather than a preplanned intervention.

As the letter writers point out, our findings of decreased C reactive protein and disappearance of fever in those treated with tocilizumab suggest a biologic impact from tocilizumab use. In addition, we suggest that tocilizumab may impact survival and mechanical ventilation rates, as reported in our results. Regarding the external validity of the study, protease inhibitors and hydroxychloroquine have now been demonstrated to not be effective in randomized controlled trials for COVID-19 treatment. Therefore, we believe it is unlikely for these agents to have impacted study outcomes significantly, particularly that of mechanical ventilation. Furthermore, though it is certainly a limitation, treatment with additional agents has been a common occurrence with COVID-19 treatment-related trials and is by no means unique to our study.
Acknowledging the limitations of a retrospective design, our study did suggest clinical benefit with tocilizumab use, particularly in reducing the proportion of patients whose condition requires mechanical ventilation. Several observational and randomized controlled trials have since replicated these findings. The recently published global phase 3 EMPACTA clinical trial has shown that tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death, although it did not improve survival. Moreover, a large retrospective evaluation by Narain et al of >5,000 hospitalized patients with COVID-19 on combination therapy reported superior survival outcome for corticosteroids with tocilizumab use when compared with standard of care treatment and treatment with corticosteroids alone or in combination with anakinra.

We thank Mombrun and Valette for their letter and their thoughtful assessment of the evidence. We agree that further prospective studies are mandatory to define tocilizumab’s place in the therapeutic arsenal for COVID-19.

Christina C. Price, MD
Frederick L. Altice, MD
Marwan M. Azar, MD
Dayna McManus, PharmD
Shana E. Gleeson, MD
Clemente J. Britto, MD
Veronica Azmy, MD
Kelsey Kaman, MD
Matthew Davis, PharmD
Geoffrey Chupp, MD
Richard Bucala, MD, PhD
Naftali Kaminski, MD
Clemente J. Britto, MD
Veronica Azmy, MD
Kelsey Kaman, MD
Matthew Davis, PharmD
Geoffrey Chupp, MD
Richard Bucala, MD, PhD
Naftali Kaminski, MD
Jeffrey E. Topal, MD
Charles Dela Cruz, MD, PhD
Maricar Malinis, MD
New Haven, CT

AFFILIATIONS: From the Section of Rheumatology, Allergy & Immunology (C. Price, V. Azmy, K. Kaman, and R. Bucala), the Section of Infectious Diseases (F. Altice, M. Azar, S. Gleeson, J. Topal, and M. Malinis), the Department of Pharmacy Services (D. McManus, M. Davis, and J. Topal), and the Section of Pulmonary, Critical Care and Sleep Medicine (C. Britto, G. Chupp, N. Kaminski, and C. Dela Cruz) Yale University School of Medicine; and the Department of Allergy and Immunology (C. Price), VA Medical Center.

FINANCIAL/NONFINANCIAL DISCLOSURES: See earlier cited article for author conflicts of interest.

CORRESPONDENCE TO: Christina C. Price, MD; e-mail: christina.price@yale.edu

Copyright © 2021 Published by Elsevier Inc under license from the American College of Chest Physicians.

DOI: https://doi.org/10.1016/j.chest.2020.12.032

References
1. Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. Chest. 2020;158(4):1397-1408.
2. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021;384:20-30.
3. Narain S, Stefanov DG, Chau AS, et al. Comparative survival analysis of immunomodulatory therapy for coronavirus disease 2019 cytokine storm. Chest. 2021;159(3):933-948.

Could Atomoxetine-Oxybutynin, a Combination of Medications Being Explored for OSA Management, Have Any Effect on Sleep Bruxism or Jaw Muscle Tone?

To the Editor:

We read with great interest the paper in CHEST (June 2020) from Taranto-Montemurro et al1 assessing the effects of a medication combination, atomoxetine-oxybutynin (ato-oxy), on different endotypic traits of OSA. The ato-oxy combination is a mixture of noradrenergic and antimuscarinic agents, and it was reported to increase genioglossus muscle responsiveness to negative esophageal pressure swings of approximately threefold in a previous study. The use of medications for individuals with specific clinical manifestations of OSA is an important avenue to personalized medicine or an adjunct therapy to CPAP or oral appliance use. Because our group has an interest in sleep bruxism (SB), a sleep motor manifestation associated with repetitive jaw muscle activity with occasional tooth grinding, a clinical question emerged: Could the ato-oxy combination also induce a rise in SB frequency or in jaw muscle tone?

Such a question is supported by the fact that genioglossus muscle responsiveness is under the control of the hypoglossal XII motoneurons and the masseter, temporalis, and digastric jaw muscles at the level of the trigeminal network. The brainstem trigeminal and the facial motor nuclei are also modulated by noradrenergic and muscarinic substances.

Although the association of OSA and SB is still debated, evidence supports a concomitance with breathing events